| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| MAH01(元) | - | 124,965,278.48 | 54,670,320.40 | 116,406,149.30 | 56,996,342.78 |
| MAH02(元) | - | 76,082,079.58 | 49,219,247.73 | 28,641,019.48 | 6,624,778.74 |
| CDMO及其他(元) | - | 149,829,358.74 | 75,203,217.72 | 177,180,935.83 | 67,133,917.87 |
| MHA(元) | - | 12,241,500.01 | - | 26,497,184.08 | - |
| MXN(元) | - | 8,792,325.53 | - | 16,835,383.38 | - |
| 抗病毒系列产品(元) | 8,085,486.73 | - | - | - | - |
| 糖尿病系列产品(元) | 94,451,427.08 | - | - | - | - |
| 新材料系列产品(元) | 30,217,881.89 | - | - | - | - |
| 其他(元) | - | - | - | 4,716.98 | - |
| 其他产品及服务(元) | 12,740,914.59 | - | - | - | - |
| 营业成本(元) | |||||
| MAH01(元) | - | 107,443,127.52 | 49,183,352.31 | 126,998,527.01 | 56,515,683.95 |
| MAH02(元) | - | 38,437,462.08 | 25,625,958.91 | 21,210,893.12 | 5,120,855.41 |
| CDMO及其他(元) | - | 111,053,981.18 | 55,040,693.64 | 133,942,985.96 | 49,281,447.42 |
| MHA(元) | - | 11,344,158.26 | - | - | - |
| MXN(元) | - | 8,766,369.23 | - | - | - |
| 抗病毒系列产品(元) | 4,870,544.27 | - | - | - | - |
| 糖尿病系列产品(元) | 64,382,262.48 | - | - | - | - |
| 新材料系列产品(元) | 28,179,158.73 | - | - | - | - |
| 其他(元) | - | - | - | - | - |
| 其他产品及服务(元) | 11,139,437.73 | - | - | - | - |
| 毛利(元) | |||||
| MAH01(元) | - | 17,522,150.96 | 5,486,968.09 | -10,592,377.71 | 480,658.83 |
| MAH02(元) | - | 37,644,617.50 | 23,593,288.82 | 7,430,126.36 | 1,503,923.33 |
| CDMO及其他(元) | - | 38,775,377.56 | 20,162,524.08 | 43,237,949.87 | 17,852,470.45 |
| MHA(元) | - | 897,341.75 | - | 26,497,184.08 | - |
| MXN(元) | - | 25,956.30 | - | 16,835,383.38 | - |
| 抗病毒系列产品(元) | 3,214,942.46 | - | - | - | - |
| 糖尿病系列产品(元) | 30,069,164.60 | - | - | - | - |
| 新材料系列产品(元) | 2,038,723.16 | - | - | - | - |
| 其他(元) | - | - | - | 4,716.98 | - |
| 其他产品及服务(元) | 1,601,476.86 | - | - | - | - |
| 毛利率(%) | |||||
| MAH01(%) | - | 14.02 | 10.04 | -9.10 | 0.84 |
| MAH02(%) | - | 49.48 | 47.94 | 25.94 | 22.70 |
| CDMO及其他(%) | - | 25.88 | 26.81 | 24.40 | 26.59 |
| MHA(%) | - | 7.33 | - | - | - |
| MXN(%) | - | 0.30 | - | - | - |
| 抗病毒系列产品(%) | 39.76 | - | - | - | - |
| 糖尿病系列产品(%) | 31.84 | - | - | - | - |
| 新材料系列产品(%) | 6.75 | - | - | - | - |
| 其他(%) | - | - | - | - | - |
| 其他产品及服务(%) | 12.57 | - | - | - | - |
| 收入构成(%) | |||||
| MAH01(%) | - | 33.60 | 30.53 | 31.84 | 43.59 |
| MAH02(%) | - | 20.46 | 27.48 | 7.83 | 5.07 |
| CDMO及其他(%) | - | 40.29 | 41.99 | 48.47 | 51.34 |
| MHA(%) | - | 3.29 | - | 7.25 | - |
| MXN(%) | - | 2.36 | - | 4.61 | - |
| 抗病毒系列产品(%) | 5.56 | - | - | - | - |
| 糖尿病系列产品(%) | 64.92 | - | - | - | - |
| 新材料系列产品(%) | 20.77 | - | - | - | - |
| 其他(%) | - | - | - | 0.00 | - |
| 其他产品及服务(%) | 8.76 | - | - | - | - |
| 毛利构成(%) | |||||
| MAH01(%) | - | 18.47 | 11.14 | -12.70 | 2.42 |
| MAH02(%) | - | 39.68 | 47.91 | 8.91 | 7.58 |
| CDMO及其他(%) | - | 40.87 | 40.95 | 51.84 | 90.00 |
| MHA(%) | - | 0.95 | - | 31.77 | - |
| MXN(%) | - | 0.03 | - | 20.18 | - |
| 抗病毒系列产品(%) | 8.71 | - | - | - | - |
| 糖尿病系列产品(%) | 81.43 | - | - | - | - |
| 新材料系列产品(%) | 5.52 | - | - | - | - |
| 其他(%) | - | - | - | 0.01 | - |
| 其他产品及服务(%) | 4.34 | - | - | - | - |